Day 2 - 23 April 2013

 

8:00-9:30 Registration
09:30 - 10:10
Plenary Session:
Chair:
Avi Treves
Caplan 2012Adult MSCs: The New Medicine
Arnold Caplan
Biology, Case Western Reserve University, Cleveland, USA

USA
10:10 - 10:40 Coffee break
Hall A - Rayman Central Hall B - Rayman West
10:40-12:20
Yehudit Cohen Sheba Tissue BanksSession E:
Translational Research & Bio Banking

Chair: Yehudit Cohen
Scientific Director - Institutional Tissue Banks, Sheba Medical Center, Israel
Israel
אריק חסוןSession F:
Supporting Environment

Chair: Arik Hasson
Executive VP, Research & Development, Kadimastem Ltd., Israel
Israel

10:40 - 11:00  

Keynote
Lectures

Stem Cell Derived Nano-Vesicles, a New Platform Targeting the Tumor Bed
Marcelle Machluf
Faculty of Biotechnology and Food Engineering, Technion - Institute of Technology, Haifa, Israel
Israel
Bringing Cell Therapies into Clinical Routine
Dirk Balshuesemann
Clinical Business, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany

11:00 - 11:20 Human Umbilical Cord Blood: More than a Source of Hematopoietic Stem Cells: Neurological Potential
Arnon Nagler
Sheba Medical Center, Ramat Gan, Israel
Israel
Building Bridges from Research to Therapy: Enabling the Utilization of Human Induced Pluripotent Stem Cells for Clinical Therapies
Thomas Fellner
Pluripotent Stem Cell Innovation Center, Lonza, Inc., Walkersville, USA
USA
11:20 - 11:40 The Role of Pluripotent Stem Cells in Modeling Human Disorders and in Drug Screening
Nissim Benvenisty
Stem Cell Unit, Genetics, Hebrew University, Jerusalem, Israel
Israel
Current Regulatory and cGMP Compliance Trends for Cellular Therapeutics and the Challenges in Translation to Late-Stage Commercial-Ready Manufacturing
Alan Moore
VP Testing and Cell Services, WuXi AppTec  Philadelphia, USA
USA
11:40 - 12:00 Building Quality Biological Collections to Maximize Use
Katheryn Shea
Precision Bioservices, Inc., Frederick, USA
USA
Intellectual Property Issues Related to Cell-Based Inventions
Leora Havin
Biotech, Ehrlich and Fenster, Ramat Gan, Israel
Israel
12:00 - 12:20 IPS Stem Cell Banking
Ida Biunno
IRGB, IRGB-CNR, Milan, Italy
italy
Stem Cells in Preclinical Studies: Choosing the Optimal Animal Model
Judith Ben-Porath
Pharmaseed, Israel
Israel
12:20 - 12:40 Human Embryonic Stem Cells – From Bench to Bedside
Benjamin Reubinoff
Sidney and Judy Swartz Embryonic Stem Cell Research Center, Hadassah University Medical Center, Jerusalem, Israel
Israel
Supportive Methodologies Utilized in the Development of an Autologous Cell Product (BGC101)
Yael Porat
BioGenCell Ltd., Sanz Medical Center, Laniado Hospital, Netanya, Israel
Israel
12:30 - 14:00 Lunch break
14:00 - 14:40
Plenary Session:
Chair:
Avi Treves
ZE photo The T-Body Approach: From the Mouse Cage to The Patient’s Bed
Zelig Eshhar
Immunology, Weizmann Institute, Rehovot, Israel

Israel
14:40 - 15:10 Coffee break
Hall A - Rayman Central Hall B - Rayman West
15:10-16:30 IMG 2381Session G:
Company-Regulator Interface
Chair: Ofra Axelrod
Deputy Director, The Institute for Standardization and Control of Pharmaceuticals, Israeli MOH, Israel
Israel

NaschitzASession H:
Funding
Chair: Anat Naschitz

Managing Director, OrbiMed Advisors, LLC
Israel

15:10 - 15:30
Keynote
Lectures

MARGARIDA

The Regulatory Challenges for the Approval of Advanced Therapies in Europe
Margarida Menezes Ferreira
Medicines Evaluation Department, INFARMED,
National Authority of Medicines and Health Products, Lisboa, Portugal
Member of the Committee for Advanced Therapies and of the Biologics Working Party/CHMP – EMA, Portugal
(15 min.)
7628969_flagbig1.gif

Picture 003FDA: Is it Really a Black Hole?
Joyce Frey-Vasconcells
Frey-Vasconcells Consulting, LLC, Sykesville, USA (15 min.)
USA

Photo ADP.jpg

EU Regulators’ Expectations for a Stem Cell Based Product Development - a Focus on CMC and NC Development
Anne Dupraz-Poiseau
Voisin Consulting Life Sciences, France (15 min.)
france

rachel

A Harmonized Approach in Regulation of PLX-PAD
Racheli Ofir
Intellectual Property & Senior Scientist, Pluristem, Haifa, Israel (15 min.)

Israel

 

104714569Special Panel - Meet the Regulator:
Audience Questions and Open Discussion 
(20 min.)

 

The Office of the Israel Chief Scientist Incentives for R&D in Cell Therapy, Regenerative Medicine and Stem Cells
Janette Lazarovits
The Office of the Chief Scientist, Israel
Israel

15:30 - 15:50 Pontifax, Vision and Investment Strategy
Silvia Noiman
Pontifax, Israel
Israel
15:50 - 16:10 Syndicate Innovation Venturing
Alain Vertes
Park BioVentures, New York, NY, USA
USA
16:10 - 16:30

The Israeli Cell Therapy Landscape
Avi Treves
Sheba Cancer Research Center, Israel
Israel

16:30-16:40 Short break
16:40 – 17:20
Plenary Session:
Chair:
Michel Revel
Chief Scientific
Officer,
Kadimastem, Ltd.
Intraspinal Stem Cell Transplantation in ALS: Results of the First Phase 1 FDA Clinical Trial
Tamir Ben Hur
Department of Neurology, Hadassah University Medical Center, Jerulem, Israel
Israel
17:20 – 17:35 Shosh MerchavClosing
Shosh Merchav
CEO, Multifacet Biosolutions Ltd., Israel, Co-Chairman Israstem 2013
Israel

 This program is subject to change

israstem-day1

<p>&nbsp;</p>
<table style="border-color: #5c5d5b; border-width: 1px; border-style: solid;" border="1" cellpadding="5">
<tbody>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">8:00-9:30</td>
<td colspan="3" bgcolor="#FFCC66" valign="top">Registration</td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">09:30 - 10:10<br />Plenary Session:<br /><strong>Chair: <br />Avi Treves</strong></td>
<td colspan="3" bgcolor="#FFF0D2" valign="top"><img style="margin: 10px; float: left;" alt="Caplan 2012" src="/images/Caplan_2012.jpg" height="75" width="61" /><strong><a href="/israstem-abs/out_of_pdf/adultmscsth_Arnold_Caplan.pdf" target="_blank">Adult MSCs: The New Medicine </a></strong><br /><span style="color: #ff6600;"><strong>Arnold Caplan</strong></span><em><br />Biology, Case Western Reserve University, Cleveland, USA</em><br /><em><strong><img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></strong></em><em><br /></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">10:10 - 10:40</td>
<td colspan="2" bgcolor="#FFFF99" valign="top">Coffee break</td>
</tr>
<tr bgcolor="#FFCC66">
<td colspan="3" bgcolor="#99CC00" height="3" nowrap="nowrap"></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">10:40-12:20</td>
<td bgcolor="#E4E9D8" valign="top" width="50%">
<div>
<div><span><strong><strong><em><img style="margin-left: 10px; margin-right: 10px; float: left;" alt="Yehudit Cohen Sheba Tissue Banks" src="/images/Israstem13/Yehudit_Cohen_Sheba_Tissue_Banks.jpg" height="78" width="56" /></em>Session E:</strong><br />Translational Research &amp; Bio Banking</strong><br /><strong><span style="color: #ff6600;">Chair: Yehudit Cohen</span><em><br /></em></strong><em>Scientific Director - Institutional Tissue Banks, Sheba Medical Center, Israel<br /><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></span></div>
</div>
<em></em></td>
<td bgcolor="#E4E9D8" valign="top" width="50%"><strong><strong><img style="margin-left: 10px; margin-right: 10px; float: left;" alt="אריק חסון" src="/images/Israstem13/%D7%90%D7%A8%D7%99%D7%A7_%D7%97%D7%A1%D7%95%D7%9F.jpg" height="77" width="55" />Session F:</strong><br />Supporting Environment </strong><br /><span style="color: #ff6600;"><strong>Chair: Arik Hasson</strong></span><em><br /> Executive VP, Research &amp; Development, Kadimastem Ltd., Israel<br /><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">
<p><span>10:40 - 11:00</span> <span>&nbsp;</span></p>
<p><span><strong>Keynote</strong><br /><strong> Lectures</strong><br /><br /></span></p></td>
<td bgcolor="#FFF0D2" valign="top"><strong><a href="/israstem-abs/out_of_pdf/stemcellderiv_Marcelle_Machluf.pdf" target="_blank">Stem Cell Derived Nano-Vesicles, a New Platform Targeting the Tumor Bed </a></strong><br /><span style="color: #ff6600;"><strong>Marcelle Machluf</strong> </span><br /><em>Faculty of Biotechnology and Food Engineering, Institute of Technology, Haifa, Israel<br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em></td>
<td bgcolor="#FFF0D2" valign="top"><strong><a href="/israstem-abs/out_of_pdf/bringingcellt_Dirk_Balshuesemann.pdf" target="_blank">Bringing Cell Therapies into Clinical Routine</a></strong><br /><span style="color: #ff6600;"><strong>Dirk Balshuesemann</strong></span><em><br />Clinical Business, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany<br /><em><img src="http://isranalytica.org.il/images/DE-flag.gif" height="23" width="35" /></em><br /></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">11:00 - 11:20</td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/humanumbilical_Arnon_Nagler.pdf" target="_blank">Human Umbilical Cord Blood: More than a Source of Hematopoietic Stem Cells: Neurological Potential</a><br /><span style="color: #ff6600;">Arnon Nagler</span><br /></strong><em>Chaim Sheba Medical Center, Ramat Gan, Israel<br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em><br /></em></td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/buildingbridge_Thomas_Fellner.pdf" target="_blank">Building Bridges from Research to Therapy: Enabling the Utilization of Human Induced Pluripotent Stem Cells for Clinical Therapies</a></strong><br /><span style="color: #ff6600;"><strong>Thomas Fellner</strong></span><em><br />Pluripotent Stem Cell Innovation Center, Lonza, Inc., Walkersville, USA<br /><em><strong><img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></strong></em><br /></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">11:20 - 11:40</td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/theroleofplu_Nissim_Benvenisty.pdf" target="_blank">The Role of Pluripotent Stem Cells in Modeling Human Disorders and in Drug Screening</a><br /><span style="color: #ff6600;">Nissim Benvenisty</span><br /></strong><em>Stem Cell Unit, Genetics, Hebrew University, Jerusalem, Israel<br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em><br /></em></td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/currentregulat_Alan__Moore.pdf" target="_blank">Current Regulatory and cGMP Compliance Trends for Cellular Therapeutics and the Challenges in </a></strong><a href="/israstem-abs/out_of_pdf/currentregulat_Alan__Moore.pdf"><strong>Translation to Late-Stage Commercial-Ready Manufacturing</strong></a><strong></strong><br /><span style="color: #ff6600;"><strong>Alan Moore<em><br /></em></strong></span><em>VP Testing and Cell Services, WuXi AppTec&nbsp; Philadelphia, USA<br /><em><strong><img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></strong></em><br /></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">11:40 - 12:00</td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/buildingqualit_Katheryn_Shea.pdf" target="_blank">Building Quality Biological Collections to Maximize Use</a><br /><span style="color: #ff6600;">Katheryn Shea</span><br /></strong><em>Precision Bioservices, Inc., Frederick, USA<br /><em><strong><img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></strong></em><br /></em></td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/intellectualpr_Hadassa_Waterman.pdf" target="_blank">Intellectual Property Issues Related to </a></strong><a href="/israstem-abs/out_of_pdf/intellectualpr_Hadassa_Waterman.pdf"><strong>Cell-Based Inventions</strong></a><strong></strong><br /><strong><span style="color: #ff6600;">Hadassa Waterman</span><em><br /></em></strong><em>Biotech, Ehrlich and Fenster, Ramat Gan, Israel<br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em><br /></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">12:00 - 12:20</td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/ipsstemcellb_Ida_Biunno.pdf" target="_blank">IPS Stem Cell Banking</a><br /><span style="color: #ff6600;">Ida Biunno</span><br /></strong><em>IRGB, IRGB-CNR, Milan, Italy<br /><em><em><img src="http://isranalytica.org.il/images/italy-flag.jpg" alt="italy" height="23" width="35" /></em></em><br /></em></td>
<td valign="top"><strong><a href="/israstem-abs/out_of_pdf/stemcellsinp_Judith_Ben-Porath.pdf" target="_blank">Stem Cells in Preclinical Studies: Choosing the </a></strong><a href="/israstem-abs/out_of_pdf/stemcellsinp_Judith_Ben-Porath.pdf"><strong>Optimal Animal Model</strong></a><br /><strong><span style="color: #ff6600;">Judith Ben-Porath</span><em><br /></em></strong><em>Pharmaseed, Israel<br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em><br /></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">12:20 - 14:00</td>
<td colspan="3" bgcolor="#FFFF99" valign="top">Lunch break</td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">14:00 - 14:40<br />Plenary Session:<br /><span style="color: #000000;"><strong>Chair: <br />Avi Treves</strong></span></td>
<td colspan="3" bgcolor="#FFF0D2" valign="top"><span><img style="margin: 10px; float: left;" alt="ZE photo" src="/images/Israstem13/ZE_photo.jpg" height="84" width="60" /></span> <strong><a href="/israstem-abs/out_of_pdf/thet-bodyappr_Zelig_Eshhar.pdf" target="_blank">The T-Body Approach: From the Mouse Cage to The Patient’s Bed</a></strong><br /><span style="color: #ff6600;"><strong>Zelig Eshhar</strong></span><em colspan="3" bgcolor="#FFF0D2"> <br />Immunology, Weizmann Institute, Rehovot, Israel</em><br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em><strong><br /></strong><em><em><em></em></em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">14:40 - 15:10</td>
<td colspan="2" bgcolor="#FFFF99" valign="top">Coffee break</td>
</tr>
<tr bgcolor="#99CC00">
<td colspan="3" height="3" nowrap="nowrap"></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">15:10-16:30</td>
<td bgcolor="#E4E9D8" valign="top"><p><strong><em><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em>Session G:</strong><br />
    Funding<strong><br>
    Chair: Anat Naschitz</strong> <br>
    Managing Director, OrbiMed Advisors, LLC<em><br style="margin: 10px; float: left;" alt="IMG 2381" src="/images/Israstem13/IMG_2381.JPG" height="75" width="58" />
    </em></p>  </td>
<td colspan="2" bgcolor="#E4E9D8" valign="top"><strong><strong><strong><strong><img style="margin: 10px; float: left;" alt="IMG 2381" src="/images/Israstem13/IMG_2381.JPG" height="75" width="58" />Session H:</strong><br />Company-Regulator Interface <br /><span style="color: #ff6600;">Chair: Ofra Axelrod</span><br /></strong><em>Deputy Director, The Institute for Standardization and Control of Pharmaceuticals, Israeli MOH, Israel<br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em></strong></strong><em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap"><span>15:10 - 15:30</span> <span><br /><strong>Keynote</strong><br /><strong> Lectures</strong></span></td>
<td bgcolor="#FFF0D2" valign="top">
<p><strong>The Office of the Israel Chief Scientist Incentives for R&amp;D in Cell Therapy, Regenerative Medicine and Stem Cells</strong><br />
  <span style="color: #ff6600;"><strong>Janette Lazarovits</strong></span><br />
  <em>The Office of the Chief Scientist</em></p></td>
<td colspan="2" rowspan="4" valign="top" bgcolor="#FFFFFF"><p><span><strong><a href="/israstem-abs/out_of_pdf/theregulatory_Margarida__Menezes_Ferreira.pdf" target="_blank">The Regulatory Challenges for the Approval of Advanced Therapies in Europe </a></strong><br />
      <span style="color: #ff6600;"><strong>Margarida Menezes Ferreira</strong></span><br />
    <em>Medicines Evaluation Department, INFARMED,</em><br />
    <em>National Authority of Medicines and Health Products, Lisboa, Portugal</em><br />
    <em>Member of the Committee for Advanced Therapies and of the Biologics Working Party/CHMP – EMA, Portugal</em> <br />
    <span style="color: #ff6600;" color="#FF6600"><span style="font-family: verdana,geneva; font-size: x-small;" face="verdana,geneva" size="2"><i><img title="7628969_flagbig1.gif" alt="7628969_flagbig1.gif" src="http://dr.doali.co.il/admin/temp/newsletters/1006/7628969_flagbig1.gif" height="23" width="35" /></i></span></span><br />
    <br />
    <strong><a href="/israstem-abs/out_of_pdf/fdaisitrea_Joyce_Frey-Vasconcells.pdf" target="_blank">FDA: Is it Really a Black Hole?</a></strong><br />
    <span style="color: #ff6600;"><strong>Joyce Frey-Vasconcells</strong></span><br />
    <em>Frey-Vasconcells Consulting, LLC</em></span> <span><br />
    </span></p>
  <p><span><br />
        <strong><a href="/israstem-abs/out_of_pdf/euregulators_Anne__Dupraz-Poiseau.pdf" target="_blank">EU Regulators’ Expectations for a Stem Cell Based Product Development a Focus on CMC and NC Development</a></strong><br />
    <strong><span style="color: #ff6600;">Anne Dupraz-Poiseau</span></strong><br />
    <em>Voisin Consulting Life Sciences, France<br />
      <em><em><img src="/images/frlarge.gif" alt="france" height="23" width="34" /></em></em></em></span></p>
  <p><strong>A Harmonized Approach in Regulation of PLX-PAD<em><br />
    </em><span style="color: #ff6600;">Racheli Ofir</span><em><br />
    </em></strong><em>Pluristem, MATAM&nbsp; Park, Haifa, Israel (15 min.)</em></p>
  <p><span><em><em><em></em></em><em><em><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em></em><br />
    </em></span> <span><strong>&nbsp;</strong></span> <span><strong>&nbsp;</strong></span> <span><strong><span style="color: #ff6600; font-size: 12pt;"><br />
    </span></strong></span></p>
  <p><span><strong><span style="color: #ff6600; font-size: 12pt;">&nbsp;</span></strong></span></p>
  <p><span><strong><img style="float: left;" alt="104714569" src="/images/icons/104714569.jpg" height="76" width="96" /></strong></span><span><strong><span style="color: #ff6600; font-size: 12pt;">Special Panel-Meet the Regulator: <br />
    Audience Questions and Open Discussion</span><br />
  </strong></span> <strong></strong><strong></strong><strong></strong></p>  <p><em><br />
  </em></p></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">15:30 - 15:50</td>
<td bgcolor="#FFFFFF" valign="top"><strong>Pontifax, Vision and Investment Strategy</strong><br />
  <strong><span style="color: #ff6600;">Silvia Noiman</span><em><br />
  </em></strong><em>Pontifax, Israel<br />
  <em><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">15:50 - 16:10</td>
<td bgcolor="#FFFFFF" valign="top"><strong><a href="/israstem-abs/out_of_pdf/syndicateinnov_Alain_Vertes.pdf" target="_blank">Syndicate Innovation Venturing</a></strong><br />
  <span style="color: #ff6600;"><strong>Alain Vertes</strong></span><em> <br />
  Park BioVentures, New York, NY, USA<br />
  <em><strong><img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></strong></em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">16:10 - 16:30</td>
<td bgcolor="#FFFFFF" valign="top"><a target="_blank" href="/israstem-abs/out_of_pdf/theisraelicel_Avi__Treves_.pdf"><strong>The Israeli Cell Therapy Landscape</strong></a><br />
  <span style="color: #ff6600;"><strong>Avi Treves</strong></span><em><br />
Sheba Cancer Research Center, Israel<br />
<em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">16:30 – 17:10<br>
  Plenary session<strong>:<br>
  <span style="color: #ff6600;">Chair: <br>
  Michel Revel</span></strong></td>
<td colspan="3" valign="top"><span><img style="margin: 10px; float: left;" alt="EvaFeldman-BannerPhoto" src="/images/Israstem13/EvaFeldman-BannerPhoto.jpg" height="83" width="61" /></span><strong><a href="/israstem-abs/out_of_pdf/intraspinalste_Eva_Feldman,_MD,_PhD.pdf">Intraspinal Stem Cell Transplantation in ALS: Results of the First Phase 1 FDA Clinical Trial</a><br /><span style="color: #ff6600;">Eva Feldman&nbsp;</span> <br /></strong><em>Neurology University of Michigan, Ann Arbor, USA</em><br /><em><strong><img src="http://isranalytica.org.il/images/US-flag.gif" alt="USA" height="20" width="35" /></strong></em><em><br /></em><em></em></td>
</tr>
<tr>
<td bgcolor="#FFCC66" nowrap="nowrap">17:10 – 17:25</td>
<td colspan="3" valign="top"><strong><img style="margin: 10px; float: left;" alt="Shosh Merchav" src="/images/Shosh_Merchav.jpg" height="81" width="64" />Closing<br /><span style="color: #ff6600;"> Shosh Merchav</span><br /></strong><em>CEO, Multifacet Biosolutions Ltd., <em>Israel, </em>Co- Chairman Israstem 2013 <br /><em><em><img alt="Israel" src="http://isranalytica.org.il/images/israel-flag.gif" height="25" width="35" /></em></em></em></td>
</tr>
</tbody>
</table>